Table 5.
Studies on fecal microbiota transplantation in Clostridium difficile-infection, outcome data
| First author | Year | Patients enrolled (n) | Age (mean ± SD or median, range/IQR) | Male sex (n) | FU | Primary endpoint | Resolution of diarrhea | Resolution of diarrhea + free from relapse during FU |
| Aas | 2003 | 181 | 73 ± 9 | 5 | 3 mo | 90 d | 94% | \ |
| Arkkila | 2010 | 37 | 69 (24-90) | 12 mo | 92% | 86% | ||
| Aroniadis | 2013 | 132 | 70 (38-89) | 3 | 15 mo (1-42) | 1-7 d | 84%, 92%3 | 50% |
| Bansal | 2013 | 12 | 70 (31-96) | 4 | 3 mo | > 90 d | 92% | \ |
| Bobo | 2013 | 214 | 70.9 ± 11.9 | 10 | 1 mo | 30 d | 95% | \ |
| Borody | 2013 | 285 | F:36 ± 18.1 M: 31 ± 16 | 17 | 86% | |||
| Bowden | 1981 | 16 | 56 (14-85) | 7 | 12 d | 12 d | 81% | \ |
| Brandt | 2012 | 77 | 65 ± 17 | 21 | 17 mo (3-68) | 90 d | 91% | 81% |
| Byrne | 2008 | 45 | 62 (30-91) | 12 | 12 mo | 96% | ||
| Eisman | 1958 | 4 | 45-68 | 3 | < 10 d | 24-48 h | 100% | 100% |
| Elopre | 2013 | 26 | 48, 48 | 1 | 5 yr and 6 wk | 1 d | 100% | 100% |
| Fischer | 2013 | 127 | 46 ± 17 | 7 | 30 d | 7 d | 75%/, 92%/3 | 75% |
| Garborg | 2010 | 39 | 75 (53-94) | 18 | 3 mo | 80 d | 73%, 83%3 | \ |
| Hamilton | 2012 | 435 | 69 ± 21 | 12 | 2 mo | 1-2 mo | 86%, 95%3 | |
| Ihunnah | 2013 | 668 | 12 mo (3-51) | 78%, 89%3 | 78% after 12 wk | |||
| Jorup-Rönström | 2012 | 32 | 75 (27–94) | 12 | 26 mo (1-68) | 69% | ||
| Kassam | 2010 | 141 | 65.3 (26-87) | 7 | 7 mo | 24 h | 100% | |
| Kelly | 2012 | 26 | 59 (19-86) | 2 | 11 mo (2-30) | post FMT | 92% | 85% |
| Khanna | 2013 | 135 | 27 (21-48) | 8 | 1-14 d | 50% | ||
| Louie | 2013 | 259 | 6 mo | 100% | 100% | |||
| MacConnachie | 2009 | 151 | 81.5 (68-95) | 14 | 4 mo (1-6) | 5-24 wk | 73%, 80%3 | 67% |
| Mattila | 2012 | 701 | 70 (22-90) | 28 | 12 mo | 12 wk | 94% | 89% |
| Mellow | 2010 | 131 | 67 (32-87) | 7 | 5 mo (1-10) | 30 d | 92% | 85% |
| Miller | 2010 | 2 | 34-50 | 0 | 9 mo, 1 mo | 9 mo, 1 mo | 100% | \ |
| Neelakanta | 2011 | 25 | 27-39 | 1 | 12 mo, 5 mo | 2 wk, post FMT | 50% | 50% |
| Newton | 2013 | 176 | 90 d | post FMT | 94% | 76% | ||
| Potakamuri | 2013 | 13 | 73.8 ± 18.8 | 2 | 5 wk- 18 mo | > 1 mo | 92% | 46% |
| Rohlke | 2010 | 19 | 49 (29-82) | 2 | 27.2 yr (6-65) | 6 mo | 95%, 100%3 | 79% |
| Rubin | 2013 | 7418 | 63 (6-94) | 26 | 2 mo | 60 d | 79% | 58% |
| Shiekh Sroujieh | 2012 | 68 | 66 (16-93) | 100 d | 1-4 d | 100% | 100% | |
| Silverman | 2010 | 7 | 72 (30-88) | 4 | 4- 14 mo | post FMT | 100% | 100% |
| Van Nood | 2013 | 16110 | 73 ± 13 | 8 | 2.5- 5 mo | 10 wk | 81%, 94%3 | 81% |
| Yoon | 2010 | 12 | 66 (30-86) | 3 | 3 wk- 8 yr | 3-5 d | 100% | 100% |
| Youngster | 2013 | 12 | 2 mo | 8 wk | 92% | \ |
Recurrent/refractory CDI. Aas et al (18), Kassam et al (7), MacConnachie et al (15), Mattila et al (70), Mellow et al (13), Rubin et al (74), van Nood et al (16);
Severe CDI 84%, complicated CDI 92%;
Resolution of diarrhea (% of the patients) after 2 FMT's;
All patients were hospitalised at inclusion;
IBD. Hamilt et al (14): CD (6), UC (4), lymphocytic colitis (4). Neelak et al (1 UC, 1 CD). Khanna et al CD (7), UC (6). Borody et al CD (14), UC (14);
Patients were immunocompromised: upon review of their medical history, Newton et al (7) based on HIV Elopre et al (2);
Other diagnoses (12): UC (3), UC and livertransplant for PSC (1), CD(3), multivisceral transplant (2), multiple myeloma (1), lung transplant (1), renal transplant (1);
Cases included 5 pediatric (Ihunnah et al) and 2 pediatric patients (Rubin et al);
> 3 episodes (25);
Amount of patients randomised to intervention (FMT) arm. /: Outcome defined as negative stool test (PCR) after FMT only; \: No further follow up after archivieving the primary endpoint. FMT: Fecal microbiota transplantation; FU: Follow-up.